Advertisement
Table 1 Measuring success.
| Potential medical outcomes: |
| (i) Quality-of-life using validated surveys |
| (ii) Biochemical control of CAH |
| (iii) Symptomatic control of androgen excess (hair loss, acne, hirsutism, amenorrhea, etc.) |
| (iv) Compliance |
| (v) Adult height |
| (vi) Frequency of adrenal crises/hospitalizations |
| (vii) Reproductive function |
(viii) Comorbidities (obesity, hypertension, metabolic syndrome, hirsutism/polycystic ovarian syndrome  , testicular adrenal
|
rests  , and myelolipomas)
|
| Potential surgical outcomes (women): |
| (i) Number and types of surgeries |
| (ii) Complications (vaginal stenosis, urinary symptoms, urinary tract infections, etc.) |
| (iii) Functional and cosmetic results |
| (iv) Patient satisfaction |
| (v) Menstrual regularity, fertility |
| Potential behavioral health/psychosexual outcomes: |
| (i) Patient and family adjustment |
| (ii) Psychopathology (depression, anxiety, obsessive-compulsive disorder, eating disorders, substance abuse, etc.) |
| (iii) Sexual function |
| (iv) Gender identity |
